Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.40
Bid: 110.40
Ask: 111.20
Change: 0.40 (0.36%)
Spread: 0.80 (0.725%)
Open: 110.00
High: 111.20
Low: 110.00
Prev. Close: 110.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

Mon, 27th Nov 2023 19:03

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Saietta Group PLC - Towcester, England-based designer, engineer and manufacturer of 'eDrive' solutions for electric vehicles - Proposes placing and subscription of new shares to raise a minimum GBP5.2 million, pricing each share at 17 pence each. This is alongside a broker option to Canaccord Genuity Ltd for an additional GBP1.0 million. The fundraising is being conducted in two tranches: around GBP1.7 million raised via the firm fundraising and a minimum of GBP4.7 million via a conditional fundraising. The fundraising is expected to satisfy the company's working capital requirements through to the end of March 2024, by which time the company is expecting to have announced a number of major commercial developments.

----------

Syncona Ltd - London-based investor in healthcare companies - Notes that its portfolio company Autolus Therapeutics PLC submits biologics licence application to US Food & Drug Administration for obecabtagene autoleucel for patients with relapsed/refractory adult B-Cell acute lymphoblastic leukaemia. Says submission is based on data from the Felix study. Says Autolus has also made "significant" progress in preparing its manufacturing footprint for the planned commercial launch of obe-cel, with its new 70,000 square foot commercial manufacturing facility, The Nucleus, which has an initial designed capacity of 2,000 batches per year. Pending approval from the Food & Drug Administration for the biologics licence application submission, the company expects to initiate its commercial launch of obe-cel in the US in 2024. It also expects to file a marketing authorisation application for obe-cel with the European Medicines Agency in the first half of 2024.

----------

Molten Ventures PLC - London-based venture capital firm - Completes GBP55.0 million placing and subscription of 20.4 million new shares priced at 270p each, representing around 13% of all shares. The retail offer remains open and is expected to close on Tuesday at 1500 GMT.

----------

Quadrise PLC - London-based residual oil technology company - Says all resolutions pass at annual general meeting, but notes resolution 3 only passed with 68% of shareholders voting in favour. Resolution 3 relates to re-appointing Non-Executive Director Dilip Shah, who is to retire by rotation. The company says on this: "The board is committed to continuing our engagement with shareholders to understand the views of those who voted against resolution 3 and will consult with them over the next few months to listen carefully to feedback and determine any next steps."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
17 Apr 2020 06:08

Syncona, Arix Note US FDA Acceptance Of Autolus Drug Application

Syncona, Arix Note US FDA Acceptance Of Autolus Drug Application

Read more
31 Mar 2020 16:20

Director dealings: Syncona chair acquires shares

(Sharecast News) - Syncona revealed on Tuesday that chairperson Melanie Gee had acquired 26,500 ordinary shares in the FTSE 250-listed life sciences investor.

Read more
23 Mar 2020 09:36

Syncona flags delays to clinical programmes amid pandemic

(Sharecast News) - Syncona updated the market on its trading amid the Covid-19 coronavirus pandemic on Monday, reporting that since the start of the outbreak, it had taken measures to protect its employees, primarily centred around remote working, to help ensure it could continue to operate with as minimal disruption as possible.

Read more
23 Mar 2020 09:36

Syncona Expects Delays In Clinical Trials Due To Virus Disruption

Syncona Expects Delays In Clinical Trials Due To Virus Disruption

Read more
20 Mar 2020 15:57

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

Read more
5 Mar 2020 15:41

DIRECTOR DEALINGS SUMMARY: IAG Chair And Director Spend EUR1.2 Million

DIRECTOR DEALINGS SUMMARY: IAG Chair And Director Spend EUR1.2 Million

Read more
24 Feb 2020 12:28

Monday broker round-up

(Sharecast News) - Rentokil: Jefferies upgrades to buy with a target price of 620p.

Read more
12 Feb 2020 15:35

Syncona Investee Presents Positive Data For Fabry, Gaucher Studies

Syncona Investee Presents Positive Data For Fabry, Gaucher Studies

Read more
7 Feb 2020 14:37

Syncona Investee Freeline Reports Positive Data From FLT180a Trial

Syncona Investee Freeline Reports Positive Data From FLT180a Trial

Read more
4 Feb 2020 11:33

Syncona pleased at end of 'productive' quarter

(Sharecast News) - Healthcare investment company Syncona updated the market on the quarter ended 31 December on Tuesday, reporting that its had expanded, invested in and advanced its portfolio in the period.

Read more
4 Feb 2020 10:51

Syncona Net Assets Rise Slightly In "Productive" Third Quarter

Syncona Net Assets Rise Slightly In "Productive" Third Quarter

Read more
30 Jan 2020 16:34

Syncona, Arix Note New Data From Autolus Trial Of AUTO3 Cell Therapy

Syncona, Arix Note New Data From Autolus Trial Of AUTO3 Cell Therapy

Read more
23 Jan 2020 09:00

Syncona, Arix Note Pricing Of Public Offering By Autolus Therapeutics

Syncona, Arix Note Pricing Of Public Offering By Autolus Therapeutics

Read more
23 Jan 2020 08:14

Syncona puts $15m into Autolus US offering

(Sharecast News) - Healthcare investment company Syncona announced on Thursday that its portfolio company, Autolus Therapeutics, had confirmed the pricing of its underwritten public offering in the United States.

Read more
19 Dec 2019 08:58

Syncona Commits USD80 Million Investment Into Freeline Therapeutics

Syncona Commits USD80 Million Investment Into Freeline Therapeutics

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.